Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avai Bio (AVAI) EBIT (2018 - 2025)

Avai Bio's EBIT history spans 6 years, with the latest figure at -$4.0 million for Q1 2024.

  • On a quarterly basis, EBIT fell 268.83% to -$4.0 million in Q1 2024 year-over-year; TTM through Mar 2024 was -$2.1 million, a 151.02% decrease, with the full-year FY2025 number at -$1.1 million, up 46.34% from a year prior.
  • EBIT hit -$4.0 million in Q1 2024 for Avai Bio, down from $1.0 million in the prior quarter.
  • Over the last five years, EBIT for AVAI hit a ceiling of $1.0 million in Q4 2023 and a floor of -$4.0 million in Q1 2024.
  • Historically, EBIT has averaged -$255019.2 across 4 years, with a median of $66221.5 in 2020.
  • The widest YoY moves for EBIT: up 4203.92% in 2020, down 1770.01% in 2020.
  • Tracing AVAI's EBIT over 4 years: stood at $417163.0 in 2020, then plummeted by 73.52% to $110471.0 in 2022, then skyrocketed by 817.8% to $1.0 million in 2023, then plummeted by 489.93% to -$4.0 million in 2024.
  • Business Quant data shows EBIT for AVAI at -$4.0 million in Q1 2024, $1.0 million in Q4 2023, and $399621.0 in Q3 2023.